Evidence map›Paper›PMID 26939910›Full record

ReviewNature reviews. Drug discovery2016

Altering the course of schizophrenia: progress and perspectives.

Mark J Millan, Annie Andrieux, George Bartzokis, Kristin Cadenhead, Paola Dazzan, Paolo Fusar-Poli, Jürgen Gallinat, Jay Giedd, Dennis R Grayson, Markus Heinrichs and 17 more

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Drug discovery, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07408934 (A Randomized Controlled Trial of Group Cognitive Behavioral Therapy), which is not on this map. Cited by 259 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
259citing papers in PubMed, 11 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07408934 naenrolling by invitationnot on this mapstarted 2024, after this paper: background citation

A Randomized Controlled Trial of Group Cognitive Behavioral Therapy (the Feeling Safe Programme) for Psychosis

TypeinterventionalSponsorThe Royal Ottawa Mental Health CentreRan2024 to 2027Enrolled50ConditionsSchizophrenia and Schizoaffective DisorderArmsCognitive Behavioral Therapy for Psychosis
3 · Its place in the literature

Who cites it

259 citing papers in PubMed, 11 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Oxytocin modulates hippocampal perfusion in people at clinical high risk for psychosis.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019
    Trial
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

199 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Mark J MillanPole for Innovation in Neuropsychiatry, Institut de Recherche (IDR) Servier, 78290 Croissy-sur-Seine, France.
Annie AndrieuxInserm, U836, Physiopathologie du cytosquelette, Grenoble Institut des Neurosciences, 38700 Grenoble, France.
George BartzokisDepartment of Psychiatry, The David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California 90095, USA.
Kristin CadenheadDepartment of Psychiatry, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, USA.
Paola DazzanDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK.
Paolo Fusar-PoliDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK.
Jürgen GallinatPsychiatrische Universitätsklinik der Charité im Saint Hedwig-Krankenhaus, 10115 Berlin, Germany.
Jay GieddChild Psychiatry Branch, Department of Psychiatry, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, USA.
Dennis R GraysonDepartment of Psychiatry, University of Illinois at Chicago, Chicago, Illinois 60612, USA.
Markus HeinrichsFreiburg Brain Imaging Center, University of Freiburg, 79106 Freiburg, Germany.
René KahnDepartment of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, 3584 CX Utrecht, Netherlands.
Marie-Odile KrebsService de Psychiatrie, Centre Hospitalier Sainte-Anne, 75014 Paris, France.
Marion LeboyerInserm, U955, Psychopathologie et génétique des maladies psychiatriques, 94000 Créteil, Paris, France.
David LewisDepartment of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA.
Oscar MarinMedical Research Council (MRC) Centre for Developmental Neurobiology, King's College London, London SE1 1UL, UK.
Philippe MarinLe Centre National de la Recherche Scientifique (CNRS), UMR-5203, Institut de Génomique Fonctionnelle, F-34000 Montpellier, France.
Andreas Meyer-LindenbergCentral Institute for Mental Health, Medical Faculty Mannheim, University of Heidelberg, J5, Mannheim, Germany.
Patrick McGorryOrygen, the National Centre of Excellence in Youth Mental Health, Parkville, Victoria 3052, Australia.
Philip McGuireDepartment of Psychosis Studies, Institute of Psychiatry, King's College London, London SE5 8AF UK.
Michael J OwenMedical Research Council (MRC) Centre for Neuropsychiatric Genetics and Genomics, Institute of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff CF24 4HQ, UK.
Paul PattersonInstitute of Neuroscience and Psychology, University of Glasgow, Glasgow G12 8QB, UK.
Akira SawaJohns Hopkins University Schools of Medicine and Public Health, Baltimore, Maryland MD21205, USA.
Michael SpeddingSpedding Research Solutions SARL, 78110 le Vesinet, France.
Peter UhlhaasInstitute of Neuroscience and Psychology, University of Glasgow, Glasgow G12 8QB, UK.
Flora VaccarinoChild Study Center, Yale School of Medicine, New Haven, Connecticut 06519, USA.
Claes WahlestedtDepartment of Psychiatry and Behavioural Sciences, University of Miami Miller School of Medicine, Miami 33136, Florida, USA.
Daniel WeinbergerLieber Institute for Brain Development, Johns Hopkins University School of Medicine, Baltimore, Maryland MD21205, USA.

Funding

Medical Research Council G0800509Medical Research Council MR/L010305/1Medical Research Council MR/N026063/1
6 · The paper itself

Abstract

Despite a lack of recent progress in the treatment of schizophrenia, our understanding of its genetic and environmental causes has considerably improved, and their relationship to aberrant patterns of neurodevelopment has become clearer. This raises the possibility that 'disease-modifying' strategies could alter the course to - and of - this debilitating disorder, rather than simply alleviating symptoms. A promising window for course-altering intervention is around the time of the first episode of psychosis, especially in young people at risk of transition to schizophrenia. Indeed, studies performed in both individuals at risk of developing schizophrenia and rodent models for schizophrenia suggest that pre-diagnostic pharmacotherapy and psychosocial or cognitive-behavioural interventions can delay or moderate the emergence of psychosis. Of particular interest are 'hybrid' strategies that both relieve presenting symptoms and reduce the risk of transition to schizophrenia or another psychiatric disorder. This Review aims to provide a broad-based consideration of the challenges and opportunities inherent in efforts to alter the course of schizophrenia.

Indexed as

Antipsychotic AgentsHumansSchizophreniaAntipsychotic Agents

Identifiers

PMID26939910

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.